JAK2 and myeloproliferative disorder: The JAK/STAT pathway is a central pathogenic component in myelofibrosis seen in myeloproliferative neoplasm (MPN)33 and is largely due to the JAK2 V617F mutation, calreticulin mutation or c‐MPL mutation.